Advances in in vivo imaging of serotonergic neurons in neuropsychiatric disorders

Neurosci Biobehav Rev. 2004 Oct;28(6):547-63. doi: 10.1016/j.neubiorev.2004.08.004.

Abstract

Alterations of central serotonergic neurotransmission, particularly changes in the presynaptically located serotonin transporter (SERT) availability, are thought to be one of the major pathomechanisms of neuropsychiatric symptoms. Modern neuroimaging techniques such as single-photon emission computed tomography and positron emission tomography employ radiolabeled tracers, which bind to SERT, and thus, allow detection of cerebral SERT availability in vivo. We review SERT imaging studies in patients with depression, anxiety disorders, eating disorders and patients with neurological diseases. We furthermore elucidate the potential of SERT imaging techniques in estimating the effect of selective serotonin reuptake-inhibitors.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Diagnostic Imaging
  • Humans
  • Membrane Glycoproteins / genetics
  • Membrane Glycoproteins / metabolism
  • Membrane Transport Proteins / genetics
  • Membrane Transport Proteins / metabolism
  • Mental Disorders / diagnostic imaging*
  • Mental Disorders / metabolism*
  • Nerve Tissue Proteins / genetics
  • Nerve Tissue Proteins / metabolism
  • Nervous System Diseases / diagnostic imaging*
  • Nervous System Diseases / metabolism*
  • Neurons / diagnostic imaging*
  • Neurons / drug effects
  • Neurons / metabolism*
  • Positron-Emission Tomography
  • Serotonin / metabolism*
  • Serotonin Agents / pharmacology
  • Serotonin Plasma Membrane Transport Proteins
  • Tomography, Emission-Computed, Single-Photon

Substances

  • Membrane Glycoproteins
  • Membrane Transport Proteins
  • Nerve Tissue Proteins
  • SLC6A4 protein, human
  • Serotonin Agents
  • Serotonin Plasma Membrane Transport Proteins
  • Serotonin